Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH-2: Efimosfermin alfa in MASH with F2–F3 fibrosis
CTR20263158Phase 3Active
- Sponsor
- GSK
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis, sponsored by GSK. Started Aug 2026; status: active.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on CTR20263158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263158.